Vol 6, Issue 4
Pages 349–357
Published: 15 Oct 2022
Milo Giani1, Ketty Tavella2, Irene Renda1, Enrico Tartarotti1, Jacopo Nori3, Ermanno Vanzi3, Simonetta Bianchi4, Tommaso Susini1*
Article Information
Citation: Milo Giani, Ketty Tavella, Irene Renda, Enrico Tartarotti, Jacopo Nori, Ermanno Vanzi, Simonetta Bianchi, Tommaso Susini. Prognostic Role of Tumor Size Reduction >50% after Neoadjuvant Chemotherapy for Breast Cancer 6 (2022): 349-357.
DOI: 10.26502/jcsct.5079174
Share
Abstract
Purpose: We evaluated the efficacy of neoadjuvant chemotherapy in reducing locally advanced and early breast cancers size, improving breastconserving surgery rates and its long-term outcomes. Our first aim was to test whether patients achieving a partial pathological response of good quality after neoadjuvant chemotherapy (tumor shrinkage >50% from the original clinical-instrumental size to the size evaluated by the pathologist on the surgical specimen) had better disease-free and overall survival rates than those with a tumor size reduction <50%.
Keywords
Breast Conserving Surgery; Down-Staging; Long-Term Outcome; Mastectomy; Tumor Shrinkage
Breast Conserving Surgery articles; Down-Staging articles; Long-Term Outcome articles; Mastectomy articles; Tumor Shrinkage articles
Article Details
1. Introduction